Skip to content
MarketScale
‹ Back to IndustriesSciences

Getting Technical: Flying in Green Skies

The aviation industry is tackling its 2% contribution to global CO2 emissions by aiming for zero emissions by 2050. Strategies include the use of sustainable aviation fuels (SAFs), hydrogen, and battery-electric aircraft. Jason Riggs from Technetics discusses these plans and the path forward.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Technetics Group on MarketScale.

By Transportation ·
Share

Key takeaways

01

Aviation is responsible for 2% of global CO2 emissions.

02

The industry aims to achieve zero emissions by 2050.

03

Sustainable aviation fuels, hydrogen, and electric aircraft are key focus areas.

Aviation contributes to 2% of all CO2 emissions, which is something the industry wants to change. Jason Riggs, director of strategy at Technetics, spoke with Tyler Kern about some of the aviation industry’s plans to reach zero emissions by 2050 through sustainable aviation fuels (SAFs), hydrogen, and pure battery-electric aircraft.

Hydrogen as a fuel source gets talked about a lot; however, until recently, it has been mostly all talk. “There are a couple of different ways you can use hydrogen to power an aircraft,” Riggs said. “One would be to burn hydrogen in the turbo engine. The second way would be to use hydrogen in a fuel cell. The fuel cell creates electricity, and the electricity then powers electric motors. And lastly, hydrogen can also be used to manufacture sustainable aviation fuels.” This all sounds great, but what’s the hang-up?

“The challenge is when you start adding in weight of the storage tanks, and all the weight required to hold that hydrogen, that energy density drops by roughly a third to two-thirds,” Riggs said. “It’s not a perfect solution even though hydrogen in and of itself has a higher energy density than some of these competing technologies.” The technology exists to make hydrogen-fueled aircrafts a reality, but its drawbacks prevent it from being a scalable solution at present. Overall, however, it’s one that holds promise for the future.

Getting to zero emissions is more than just the emissions coming out of the jet; the production of green fuels counts too, and the industry is looking at ways to balance out both ends. Producing hydrogen fuels today is more expensive than producing traditional kerosene jet fuels. Bringing costs down will be another factor in moving the industry forward in its path toward green, and government incentives could help move the needle. However, without such intervention, green-fuel initiatives may not stand a fighting chance.

Technetics Group

Part of this channel

Technetics Group

Engineered seals and components for semiconductor, aerospace, and nuclear.

Visit the channel →

About the author

T
Transportation

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

T
Transportation
JR
Jason Riggs

Director of Strategy

Technetics

Jason Riggs is the Director of Strategy at Technetics, where he focuses on advancing sustainable aviation solutions. He is involved in initiatives aimed at reducing the aviation industry's carbon emissions and exploring alternative fuels.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512